Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8+ T cells

Forman, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107

Rouprêt, 2013, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013, Eur Urol, 64, 639, 10.1016/j.eururo.2013.06.003

Zlotta, 2009, Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy, Eur Urol, 56, 430, 10.1016/j.eururo.2009.06.028

Kurth, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031

Astobieta, 2009, Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model, J Urol, 182, 2195, 10.1016/j.juro.2009.07.016

Kim, 2014, Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models, Korean J Urol, 55, 643, 10.4111/kju.2014.55.10.643

Real, 2014, Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours, PLoS One, 9, e96849, 10.1371/journal.pone.0096849

Shariat, 2014, Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder, Urol Oncol, 32, 230, 10.1016/j.urolonc.2013.06.009

Abel, 2011, Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort, Sci World J, 11, 751, 10.1100/tsw.2011.77

Rabadan, 2011, The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables, Eur Urol, 60, 423, 10.1016/j.eururo.2011.05.033

Boubaker, 2013, The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy, Ultrastruct Pathol, 37, 249, 10.3109/01913123.2013.786772

Shen, 2013, Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models, Urology, 82, 387, 10.1016/j.urology.2013.04.007

Desgrandchamps, 2015, A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G, Eur Urol, 68, 267, 10.1016/j.eururo.2015.02.032

Ghoneim, 2005, Expression of HLA-G in cancer bladder, Egypt J Immunol, 12, 57

Yan, 2010, Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma, Hum Immunol, 71, 899, 10.1016/j.humimm.2010.06.012

LeMaoult, 2015, HLA-G: An Immune Checkpoint Molecule, Adv Immunol, 127, 33, 10.1016/bs.ai.2015.04.001

Lopez-Botet, 1997, A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells, J Exp Med, 186, 1809, 10.1084/jem.186.11.1809

Coussens, 2012, Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, 21, 309, 10.1016/j.ccr.2012.02.022

Grivas, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4

LeMaoult, 2011, Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity, J Immunol, 186, 2210, 10.4049/jimmunol.1000547

Malats, 2014, Inflammatory biomarkers and bladder cancer prognosis: a systematic review, Eur Urol, 66, 1078, 10.1016/j.eururo.2014.07.033

Kihara, 2011, C-reactive protein as a biomarker for urological cancers, Nat Rev Urol, 8, 659, 10.1038/nrurol.2011.145

Mucci, 2009, Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality, Int J Cancer, 124, 2683, 10.1002/ijc.24241

Wu, 2012, Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma, Urol Oncol, 30, 680, 10.1016/j.urolonc.2010.08.009

Italiano, 2011, Prognostic or predictive? It's time to get back to definitions!, J Clin Oncol, 29, 4718, 10.1200/JCO.2011.38.3729

Suciu-Foca, 2002, Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4, Nat Immunol, 3, 237, 10.1038/ni760

Nikolich-Zugich, 2004, Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense, J Exp Med, 200, 1347, 10.1084/jem.20040437

Rouas-Freiss, 2003, Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules, Hum Immunol, 64, 315, 10.1016/S0198-8859(02)00821-2

Grosse-Wilde, 2010, Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study, Hum Reprod, 25, 1691, 10.1093/humrep/deq120

Soukup, 2017, EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016, Eur Urol, 71, 447, 10.1016/j.eururo.2016.05.041